What Sanderling Ventures does

Sanderling Ventures is a US-based venture capital firm founded in 1979 by Robert G. McNeil, Ph.D., and is among the oldest investment firms dedicated to building new biomedical companies. The firm has operated seven sequential investment partnerships and has supported more than 90 startup biomedical companies across its history. It is headquartered in San Mateo, California, with an additional office in Montreal, Quebec, and operates with a small team of 11-50 employees including managing directors, principals, venture partners, and in-house counsel.

The firm's core offering combines seed and early-stage capital with active management participation, distinguishing it from capital-only VCs. Through its affiliated operating entity, Sanderling Management Company LLC, the firm deploys professionals with expertise in finance, accounting, law, human resources, corporate development, research management, and strategic planning directly into portfolio companies during their startup phase. This model is designed to mitigate founder dilution, accelerate clinical and operational milestones, and reduce the cost of adding senior management early. Documented results include portfolio companies reaching IND filings roughly two years sooner than typical VC-backed biomedical peers and approximately $15 million in capital saved at Actimis Pharmaceuticals over its investment life.

Sanderling's investment focus spans small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, and medical devices. The firm maintains relationships with academic research laboratories, contract manufacturing facilities, and investment bankers that its portfolio companies can access. The firm generates revenue through management fees on committed capital across its seven partnerships and through carried interest on successful realizations, although neither figure is publicly disclosed. Current leadership includes Managing Directors Fred Middleton and Timothy Mills, Ph.D., Managing Director Emeritus Timothy Wollaeger, Principal Michael Dixon, and General Counsel Paulette Taylor.

Name

Sanderling Ventures

Legal name

Sanderling Ventures

Website

https://sanderling.com

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

11–50 employees

Short description

Sanderling Ventures is a US venture capital firm founded in 1979 that provides seed and early-stage capital combined with active management participation to biomedical startups. The firm has supported over 90 portfolio companies across therapeutics, biologics, drug delivery, and medical devices through seven investment partnerships.

Ownership category

akta.pro rank

Product category

Venture Capital (Biomedical)

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

Keywords

• Biomedical venture capital
• Early-stage biotech investing
• Active portfolio management
• Seed and series financing
• Biopharmaceutical investment

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Sanderling Ventures provides seed and early-stage venture capital financing to new biomedical companies and complements that capital with active management participation during the start-up phase. Its principals and affiliated Sanderling Management Company LLC supply management leadership, administrative support, regulatory and technical expertise, and financing assistance (including relationships with investment bankers for public offerings). The firm has supported more than 90 biomedical companies since its founding in 1979, with specialization in small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, and medical devices.

Product overview

Sanderling Ventures is a venture capital firm specializing in early-stage biomedical financing and active management. Rather than offering a software product platform, the firm provides investment capital, management expertise, and operational support to early-stage biomedical companies. Their services include seed and early-stage funding, active management participation during start-up phases, strategic business development, and resource allocation support. The firm has invested in over 90 biomedical companies across sectors including biopharmaceuticals, medical devices, and healthcare IT, with specialization in small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, and medical devices.

Differentiator

Problem solved

Functional benefit

Brands

• Sanderling Management Company LLC: The management services entity employed by Sanderling Ventures that provides professionals with skills useful to startup biomedical companies, including finance, accounting, law, human resources, corporate development, and research management.

Products and services

• Early-stage biomedical venture capital financing
• Active management participation services
• Sanderling Management Company LLC management services
• Financing and public offering support
• Research and manufacturing network access

Quantifiable outcome

• Portfolio companies achieved IND filings roughly two years sooner than typical VC-backed biomedical company
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered minor and core.

• TherilliaminorOthersTherillia is a related entity connected to Sanderling Ventures, with Michael Dixon serving as CEO overseeing development of therapeutic assets including dalcetrapib
• Academic Research LaboratoriescoreStrategic or Co-development PartnerSanderling maintains relationships with academic research laboratories that portfolio companies can access for research and development support during early-stage development
• Contract Manufacturing FacilitiescoreStrategic or Co-development PartnerSanderling provides access to contract manufacturing facilities for portfolio companies requiring manufacturing capabilities during drug development

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Abingworth: Life sciences-focused venture firm with transatlantic (US/UK) presence. Comparable given sector focus and cross-border footprint similar to Sanderling's US/Canada setup.
• Domain Associates: Long-tenured healthcare venture firm investing in biopharma, medtech, and diagnostics. Highly comparable given similar sector specialization and partnership age.
• Alta Partners: Biomedical-focused venture firm with a long history of early-stage therapeutics investing. Comparable given longevity, sector focus, and stage of investing.
• Atlas Venture: Early-stage, biotech-focused venture firm that builds new companies around academic science. Directly comparable to Sanderling in stage focus, biomedical specialization, and company-building orientation.
• Frazier Healthcare Partners: Healthcare-dedicated venture and growth firm investing across biopharma and medtech. Closely comparable given its early-stage life sciences practice and long-tenured partnership model.
• Versant Ventures: Venture firm that builds and funds biomedical companies, including in-house incubation of new startups. Highly comparable company-building model and therapeutic focus to Sanderling.
• 5AM Ventures: Early-stage life sciences venture firm investing across biopharma, platforms, and medtech. Comparable stage, sector, and small-partnership structure.

Broad incumbents

• OrbiMed: One of the largest dedicated healthcare investment firms, spanning venture, growth, and public equities. Comparable biomedical focus but materially larger scale and broader stage coverage.
• Venrock: Multi-stage venture firm with a significant healthcare practice alongside technology. Comparable biomedical investing arm but operates as a generalist across sectors.
• New Enterprise Associates (NEA): Large multi-stage venture firm with a major healthcare/biopharma practice. Comparable in biomedical investing activity but materially larger scale and broader stage range than Sanderling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Sanderling-Ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments100 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanderling Ventures